Clinical Trials Logo

Recurrent Pheochromocytoma clinical trials

View clinical trials related to Recurrent Pheochromocytoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01635907 Completed - Clinical trials for Unresectable Paraganglioma

Dovitinib in Neuroendocrine Tumors

Start date: June 2012
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors. This study will also further evaluate the safety of this drug.

NCT ID: NCT01155258 Completed - Clinical trials for Stage IV Breast Cancer

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: June 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

NCT ID: NCT00655655 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.